Barinthus Biotherapeutics plc (BRNS)vsBeiGene, Ltd. (ONC)
BRNS
Barinthus Biotherapeutics plc
$0.59
+0.43%
HEALTHCARE · Cap: $23.29M
ONC
BeiGene, Ltd.
$359.05
-0.06%
HEALTHCARE · Cap: $40.64B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
BRNS
Avoid32
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BRNS.
Margin of Safety
+80.3%
Fair Value
$1785.72
Current Price
$359.05
$1426.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BRNS
The strongest argument for BRNS centers on Price/Book, Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.
Bear Case : BRNS
The primary concerns for BRNS are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.2x leaves little room for execution misses.
Key Dynamics to Monitor
BRNS profiles as a value stock while ONC is a growth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.50 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 32/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Barinthus Biotherapeutics plc
HEALTHCARE · BIOTECHNOLOGY · USA
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company is headquartered in Harwell, the United Kingdom.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?